Treatment of Patients With Nocturia

Completed · Phase 3 · Has a placebo group

Conditions studied: Nocturia

In brief

The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.

Key facts

Study ID

NCT00937859

Run by

Serenity Pharmaceuticals, Inc.

People needed

301

Starts

2009-06-01

Expected to finish

2010-07-01

Last updated by the study team

2020-09-18

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female 50 years or older
• Nocturia of 6 or more months duration averaging 2 episodes or more per night

You may not qualify if…

• CHF
• Diabetes
• Diabetes Insipidus
• Renal Insufficiency
• Hepatic Insufficiency
• Incontinence
• Illness requiring steroids
• Current or past urologic malignancy
• Nephrotic Syndrome
• Unexplained pelvic masses
• Urinary bladder neurological dysfunction
• Urinary bladder surgery or radiotherapy
• Sleep Apnea
• Pregnant or breast feeding

Where it is running

• Piedmont Medical Research Assoc. — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.